Earnings · US stocks

Halozyme Therapeutics, Inc. (HALO) earnings

Halozyme Therapeutics, Inc. published its quarterly report on 2026-11-05: net profit +39.00% year on year. The stock moved -16.25% in the 3 trading days after the report.

Report
quarterly report
Published
2026-11-05
Net profit YoY
+39.00%
Result
Good
Open earnings in Wave Radar

Stock move after the report

Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.

AfterReturnvs index
1 day-15.72%—
3 days-16.25%—
7 days-21.52%—

Report history

Over the last 8 reports, EPS beat the consensus estimate in 7 of them. The stock rose in the 3 trading days after 5 of 8 reports (average +1.66%).

PublishedEPS YoYEPSEPS surprise3 days after30 days after30d vs index
2026-11-05+39.00%2.39+1.46%-16.25%——
2026-08-06+48.10%2.28+25.53%+19.66%+31.12%+32.02%
2026-05-11+44.10%1.60+5.26%+4.22%+7.14%+7.96%
2026-02-17-119.00%-0.24-110.92%-11.80%-19.69%-14.93%
2025-11-03+35.40%1.72+5.51%+3.31%-2.61%-1.96%
2025-08-05+69.20%1.54+21.45%+3.44%+24.67%+19.70%
2025-05-06+40.50%1.11+17.14%+10.93%-10.49%-17.41%
2025-02-18+53.70%1.26+8.73%-0.26%+6.86%+15.12%

The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.

Stock valuations: HALO

How to read this

Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.